Metastatic joint involvement or inflammatory arthritis? A conundrum with immune checkpoint inhibitor-related adverse events

Rheumatology (Oxford). 2018 Apr 1;57(4):760-762. doi: 10.1093/rheumatology/kex470.

Authors

Jemima Albayda¹, Clifton O Bingham 3rd¹, Ami A Shah¹, Ronan J Kelly², Laura Cappelli¹

Affiliations

¹ Division of Rheumatology, Johns Hopkins University, Baltimore, MD, USA.
² Department of Oncology, Johns Hopkins University, Baltimore, MD, USA.

No abstract available

Publication types

Case Reports
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal / adverse effects*
Antibodies, Monoclonal / therapeutic use
Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use
Antineoplastic Agents, Immunological / administration & dosage
Antineoplastic Agents, Immunological / adverse effects
Arthritis / diagnosis
Arthritis / etiology*
Carcinoma, Non-Small-Cell Lung / diagnosis
Carcinoma, Non-Small-Cell Lung / drug therapy
Carcinoma, Non-Small-Cell Lung / secondary*
Diagnosis, Differential
Drug Therapy, Combination
Humans
Immunotherapy / adverse effects*
Ipilimumab / adverse effects*
Ipilimumab / therapeutic use
Lung Neoplasms / drug therapy
Lung Neoplasms / pathology*
Male
Middle Aged
Nivolumab
Radiography
Synovial Membrane / diagnostic imaging
Ultrasonography, Doppler

Substances

Antibodies, Monoclonal
Antineoplastic Agents
Antineoplastic Agents, Immunological
Ipilimumab
Nivolumab

Grants and funding